StockMacro
Menu

Standard BioTools

$0.63 -42% in 6 monthsMarket cap $249.1M

LAB on XNAS, Health Care, Standard BioTools Inc., job postings

Measures activity, not value. Not investment advice.

Revenue fell 22% over 12 months and the stock lost 51%, though net income hit $133.1M.

  • BadInstitutional holders fell to 104 from 140, down 26%

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Industry
Pharmaceutical preparations (Health Care)
Employees
389
Website
standardbio.com
Listed
Nasdaq, US
Last results
5 Aug 2026
Next results
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $19.4M, net income $13.5M.
Quarter to 31 Dec 2021: revenue $38.3M, net income -$9.4MQuarter to 31 Dec 2021: revenue $38.3M, net income -$9.4MQuarter to 31 Mar 2022: revenue $26.5M, net income -$76.3MQuarter to 31 Mar 2022: revenue $26.5M, net income -$76.3MQuarter to 30 Jun 2022: revenue $18.8M, net income -$63.5MQuarter to 30 Jun 2022: revenue $18.8M, net income -$63.5MQuarter to 30 Sep 2022: revenue $25.6M, net income -$29.4MQuarter to 30 Sep 2022: revenue $25.6M, net income -$29.4MQuarter to 31 Dec 2022: revenue $27.0M, net income -$20.8MQuarter to 31 Dec 2022: revenue $27.0M, net income -$20.8MQuarter to 31 Mar 2023: revenue $25.1M, net income -$16.8MQuarter to 31 Mar 2023: revenue $25.1M, net income -$16.8MQuarter to 30 Jun 2023: revenue $27.7M, net income -$17.0MQuarter to 30 Jun 2023: revenue $27.7M, net income -$17.0MQuarter to 30 Sep 2023: revenue $25.4M, net income -$21.0MQuarter to 30 Sep 2023: revenue $25.4M, net income -$21.0MQuarter to 31 Dec 2023: revenue $28.2M, net income -$19.8MQuarter to 31 Dec 2023: revenue $28.2M, net income -$19.8MQuarter to 31 Mar 2024: revenue $45.5M, net income -$32.2MQuarter to 31 Mar 2024: revenue $45.5M, net income -$32.2MQuarter to 30 Jun 2024: revenue $37.2M, net income -$45.7MQuarter to 30 Jun 2024: revenue $37.2M, net income -$45.7MQuarter to 30 Sep 2024: revenue $45.0M, net income -$26.9MQuarter to 30 Sep 2024: revenue $45.0M, net income -$26.9MQuarter to 31 Dec 2024: revenue $46.7M, net income -$34.1MQuarter to 31 Dec 2024: revenue $46.7M, net income -$34.1MQuarter to 31 Mar 2025: revenue $40.8M, net income -$26.0MQuarter to 31 Mar 2025: revenue $40.8M, net income -$26.0MQuarter to 30 Jun 2025: revenue $21.8M, net income -$33.5MQuarter to 30 Jun 2025: revenue $21.8M, net income -$33.5MQuarter to 30 Sep 2025: revenue $19.6M, net income -$34.7MQuarter to 30 Sep 2025: revenue $19.6M, net income -$34.7MQuarter to 31 Dec 2025: revenue –, net income $19.3MQuarter to 31 Mar 2026: revenue $21.1M, net income $127.1MQuarter to 31 Mar 2026: revenue $21.1M, net income $127.1MQuarter to 30 Jun 2026: revenue $20.1M, net income -$26.8MQuarter to 30 Jun 2026: revenue $20.1M, net income -$26.8MQuarter to 30 Sep 2026: revenue $19.4M, net income $13.5MQuarter to 30 Sep 2026: revenue $19.4M, net income $13.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $127.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$19.4M$13.5M
30 Jun 2026$20.1M-$26.8M
31 Mar 2026$21.1M$127.1M
31 Dec 2025–$19.3M
30 Sep 2025$19.6M-$34.7M
30 Jun 2025$21.8M-$33.5M
31 Mar 2025$40.8M-$26.0M
31 Dec 2024$46.7M-$34.1M
30 Sep 2024$45.0M-$26.9M
30 Jun 2024$37.2M-$45.7M
31 Mar 2024$45.5M-$32.2M
31 Dec 2023$28.2M-$19.8M
30 Sep 2023$25.4M-$21.0M
30 Jun 2023$27.7M-$17.0M
31 Mar 2023$25.1M-$16.8M
31 Dec 2022$27.0M-$20.8M
30 Sep 2022$25.6M-$29.4M
30 Jun 2022$18.8M-$63.5M
31 Mar 2022$26.5M-$76.3M
31 Dec 2021$38.3M-$9.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $84.4M $108.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -22% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $133.1M -$128.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.34 -$0.33
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 52.2% 49.0% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -97.5% -109% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 158% -118% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 27.9% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$98.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $461.1M $194.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $300K $299K
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$460.8M (net cash) -$194.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.00 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.41
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.0 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.45 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Standard BioToolsLAB (this company) $249.1M–3.0-22%158%
Q32 BioQTTB $249.6M7.7–––
Turn TherapeuticsTTRX $247.5Mloss–––
Lifecore BiomedicalLFCR $242.2M––––
Prelude TherapeuticsPRLD $258.5Mloss12.0+105%-247%
AltimmuneALT $258.8Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$47K

bought $47K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-26%

104 13F filers vs 140

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

73%

289.4M shares held by 13F filers (30 Sep 2026) of 394.8M outstanding (1 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.5%

2.2M shares sold short (30 Oct 2026) of 394.8M outstanding (1 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.1

2.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

2.4M shares sold short in the report before, 2.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

75%

75% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-0.9%

$19.4M vs $19.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-82%

$344K vs $1.9M (quarter ended 30 Jun 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$850K

the 12 months before: $398K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

15 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.63 on 20 Nov 2026, -51% over 12 months (12-month range $0.54 to $1.68)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $550K in the last 12 months (the 12 months before: $20.9M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, +500% on the 12 months before.
Revenue per quarter. Revenue $19.4M in the latest quarter, -0.9% on a year earlier.
Capital spending per quarter. Capital spending $344K in the latest quarter, -82% on a year earlier.
Institutional holders (13F filers). 104 13F filers reported holding it in the latest 13F quarter, -28% on a year earlier.
Federal obligations. Federal obligations: $205K published in the last 12 months, -80% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Nov 20268-K and other filingsStockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closing
19 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 20268-K and other filingsA major agreement ended
24 Jul 20268-K and other filingsDelisting notice or listing transfer
18 Jun 20268-K and other filingsDirector or officer change
8 Jun 20268-K and other filingsDirector or officer change
3 Jun 20268-K and other filingsDirector or officer change
28 May 20268-K and other filingsDirector or officer change
28 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Apr 20268-K and other filingsDelisting notice or listing transfer
30 Jan 20268-K and other filingsCompleted an acquisition or asset sale
17 Sep 20258-K and other filingsRestructuring costs announced
3 Sep 20258-K and other filingsRestructuring costs announced
12 Aug 20258-K and other filingsReport will be filed late
1 Aug 20258-K and other filingsDirector or officer change
20 Jun 20258-K and other filingsDirector or officer change
20 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.1M vs usual 958K (2025-03-31); 6.5x the same period a year earlier
18 Mar 2025Sharp changeQuarterly revenue change: quarterly revenue change, 46.7M vs usual 27.9M (2024-12-31); 1.7x the same period a year earlier
10 Jan 20258-K and other filingsDirector or officer change
12 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 45.0M vs usual 27.3M (2024-09-30); 1.8x the same period a year earlier
7 Nov 20248-K and other filingsDirector or officer change
30 Aug 20248-K and other filingsDirector or officer change
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 37.2M vs usual 26.3M (2024-06-30); 1.3x the same period a year earlier
31 Jul 20248-K and other filingsDirector or officer change
1 Jul 20248-K and other filingsDirector or officer change
1 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jun 2024Sharp changeShort interest spike: short interest spike, 13.3M vs usual 4.1M (2024-05-31); 4.8x the same period a year earlier
28 May 2024Sharp changeShort interest spike: short interest spike, 12.1M vs usual 3.9M (2024-05-15); 3.8x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 67 vs usual 13 (2024-03-31); 5.6x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 11.4M vs usual 3.6M (2024-04-30); 3.5x the same period a year earlier
14 May 2024Sharp changeQuarterly revenue change: quarterly revenue change, 45.5M vs usual 26.1M (2024-03-31); 1.8x the same period a year earlier
8 May 20248-K and other filingsCompleted an acquisition or asset sale
30 Apr 2024Sharp changeShort interest spike: short interest spike, 11.3M vs usual 3.5M (2024-04-15); 3.6x the same period a year earlier
25 Apr 20248-K and other filingsRestructuring costs announced
16 Apr 2024Sharp changeShort interest spike: short interest spike, 10.2M vs usual 3.3M (2024-03-28); 3.8x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 9.3M vs usual 3.2M (2024-03-15); 3.6x the same period a year earlier
18 Mar 20248-K and other filingsDirector or officer change
12 Mar 2024Sharp changeShort interest spike: short interest spike, 7.9M vs usual 3.2M (2024-02-29); 2.6x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 8.1M vs usual 3.1M (2024-02-15); 3.0x the same period a year earlier
13 Feb 2024Sharp changeShort interest spike: short interest spike, 7.3M vs usual 3.0M (2024-01-31); 2.5x the same period a year earlier
30 Jan 2024Sharp changeShort interest spike: short interest spike, 7.7M vs usual 2.9M (2024-01-12); 2.6x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 5.8M vs usual 2.9M (2023-12-29); 1.8x the same period a year earlier
5 Jan 20248-K and other filingsCompleted an acquisition or asset sale
5 Jan 20248-K and other filingsDirector or officer change
5 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jan 2024Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.9M (2023-12-15); 1.5x the same period a year earlier
28 Jul 20238-K and other filingsDirector or officer change
16 Jun 20238-K and other filingsDirector or officer change
15 May 20238-K and other filingsDirector or officer change
3 May 20238-K and other filingsDirector or officer change
16 Mar 20238-K and other filingsDirector or officer change
16 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Aug 20228-K and other filingsRestructuring costs announced
3 Aug 20228-K and other filingsDirector or officer change
7 Jul 20228-K and other filingsDirector or officer change
27 Jun 20228-K and other filingsDirector or officer change
5 Apr 20228-K and other filingsA major agreement ended
5 Apr 20228-K and other filingsDirector or officer change
29 Mar 20228-K and other filingsDirector or officer change
16 Mar 20228-K and other filingsDirector or officer change
9 Mar 2022Lobbying filinglobbying engagement terminated (MERCURY PUBLIC AFFAIRS, LLC)
24 Jan 20228-K and other filingsDirector or officer change
24 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Apr 2022: $2.7M published
Month from 1 May 2022: $2.5M published
Month from 1 Jun 2022: $1.0M published
Month from 1 Aug 2022: $1.5M published
Month from 1 May 2023: $2.8M published
Month from 1 Mar 2024: $646K published
Month from 1 May 2024: $5.3M published
Month from 1 Aug 2024: $12.6M published
Month from 1 Mar 2025: $5.2M published
Month from 1 May 2025: -$57K published
Month from 1 Aug 2025: $1.1M published
Month from 1 Sep 2025: $766K published
Month from 1 Nov 2025: $13.9M published
Month from 1 Dec 2025: $503K published
Month from 1 Nov 2026: $47K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Apr 2026: 4 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $38.3M, -14% on a year earlier; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $26.5M, -19% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $18.8M, -39% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $25.6M, -10% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $27.0M, -29% on a year earlier; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $25.1M, -5.2% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $27.7M, +47% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $25.4M, -1.1% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $28.2M, +4.3% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $45.5M, +81% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $37.2M, +34% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $45.0M, +77% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $46.7M, +66% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $40.8M, -10% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $21.8M, -42% on a year earlier; public on 16 Aug 2025
Quarter ended 30 Sep 2025: $19.6M, -57% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $21.1M, -48% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $20.1M, -7.6% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $19.4M, -0.9% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $463K; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $868K, -87% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $938K, -78% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, -26% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $755K, +63% on a year earlier; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $1.0M, +16% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $838K, -11% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $905K, -28% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $78K, -90% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $781K, -23% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $1.9M, +131% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.3M, +149% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $3.4M, +4236% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $5.1M, +547% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.9M, -2.6% on a year earlier; public on 16 Aug 2025
Quarter ended 30 Sep 2025: $886K, -61% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $476K, -86% on a year earlier; public on 17 Mar 2026
Quarter ended 31 Mar 2026: $570K, -89% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $344K, -82% on a year earlier; public on 6 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 111; public on 14 Feb 2022
31 Mar 2022 report: 101; public on 16 May 2022
30 Jun 2022 report: 86; public on 15 Aug 2022
30 Sep 2022 report: 64; public on 14 Nov 2022
31 Dec 2022 report: 66; public on 14 Feb 2023
31 Mar 2023 report: 65; public on 15 May 2023
30 Jun 2023 report: 67; public on 14 Aug 2023
30 Sep 2023 report: 71; public on 14 Nov 2023
31 Dec 2023 report: 82; public on 14 Feb 2024
31 Mar 2024 report: 141; public on 15 May 2024
30 Jun 2024 report: 138; public on 14 Aug 2024
30 Sep 2024 report: 137; public on 14 Nov 2024
31 Dec 2024 report: 142; public on 14 Feb 2025
31 Mar 2025 report: 145; public on 15 May 2025
30 Jun 2025 report: 152; public on 14 Aug 2025
30 Sep 2025 report: 145; public on 14 Nov 2025
31 Dec 2025 report: 150; public on 17 Feb 2026
31 Mar 2026 report: 150; public on 15 May 2026
30 Jun 2026 report: 140; public on 14 Aug 2026
30 Sep 2026 report: 104; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $0 published
Month from 1 Feb 2022: $47K published
Month from 1 Mar 2022: $53K published
Month from 1 Apr 2022: -$26K published
Month from 1 May 2022: -$2K published
Month from 1 Jun 2022: $34K published
Month from 1 Jul 2022: $21K published
Month from 1 Aug 2022: $356K published
Month from 1 Sep 2022: $244K published
Month from 1 Dec 2022: $61K published
Month from 1 Mar 2023: $155K published
Month from 1 Apr 2023: $21K published
Month from 1 May 2023: $18K published
Month from 1 Jun 2023: $0 published
Month from 1 Jul 2023: $230K published
Month from 1 Aug 2023: $147K published
Month from 1 Sep 2023: $125K published
Month from 1 Feb 2024: $55K published
Month from 1 Mar 2024: -$1K published
Month from 1 Apr 2024: -$167K published
Month from 1 May 2024: $78K published
Month from 1 Jun 2024: $113K published
Month from 1 Jul 2024: $33K published
Month from 1 Aug 2024: $14K published
Month from 1 Sep 2024: $169K published
Month from 1 Dec 2024: -$8K published
Month from 1 Mar 2025: $56K published
Month from 1 Apr 2025: $86K published
Month from 1 Jun 2025: $16K published
Month from 1 Jul 2025: $49K published
Month from 1 Aug 2025: $294K published
Month from 1 Sep 2025: $543K published
Month from 1 Mar 2026: $15K published
Month from 1 Apr 2026: $17K published
Month from 1 Jun 2026: $0 published
Month from 1 Jul 2026: $0 published
Month from 1 Aug 2026: $130K published
Month from 1 Sep 2026: $42K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $344K (30 Jun 2026), 82% below its normal quarter of $1.9M; higher than 22% of its own history.
  • Insider net buying (open market): Insiders bought a net $550K in the last 12 months (the 12 months before: $20.9M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 6 published in the last 12 months, +500% on the 12 months before.
  • Revenue per quarter: Revenue $19.4M in the latest quarter, -0.9% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: no sales; 1 purchase, $47K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
5 Nov 2026Thomas D. CareyDirectorBuy75,000$0.63$47KForm 4
4 Dec 2025Casdin Private Growth Equity Fund GP, LLC and 7 othersDirectorBuy350,000$1.44$503KForm 4
26 Nov 2025Casdin Partners GP, LLC and 7 othersDirector, 10% ownerBuy7,700,000$1.30$10.0MForm 4
20 Nov 2025Eli Casdin and 7 othersDirector, 10% ownerBuy1,075,000$1.28$1.4MForm 4
17 Nov 2025Casdin Partners Master Fund, L.P. and 7 othersDirector, 10% ownerBuy925,000$1.22$1.1MForm 4
12 Nov 2025Casdin Partners GP, LLC and 7 othersDirector, 10% ownerBuy1,175,000$1.17$1.4MForm 4
11 Sep 2025Casdin Partners Master Fund, L.P. and 7 othersDirector, 10% ownerBuy100,000$1.29$129KForm 4
5 Sep 2025Eli Casdin and 7 othersDirector, 10% ownerBuy500,000$1.27$638KForm 4

104 institutions reported shares at the end of Q3 2026, 73% of the shares outstanding; 8 opened a position, 41 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Casdin Capital, LLC88.8M22.5%$65.8MNo change
Viking Global Investors LP58.7M14.9%$43.4MNo change
Long Focus Capital Management, LLC25.3M6.41%$18.7M+1.8M+7.7%
Mak Capital One LLC25.0M6.33%$18.5M-3.8M-13%
Vanguard Capital Management LLC12.5M3.17%$9.3M+244K+2.0%
BlackRock, Inc.8.3M2.09%$6.1M+1,4530%
Hollow Brook Wealth Management LLC5.2M1.32%$3.9M-303K-5.5%
Qube Research & Technologies Ltd4.9M1.25%$3.7M+117K+2.4%
Neuberger Berman Group LLC4.3M1.10%$3.2M-609K-12%
D. E. Shaw & Co., Inc.4.0M1.02%$3.0M+1.2M+43%

Federal contracts

All 2 federal contracts

No new award in 12 months; the latest was signed 30 Jul 2020. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
30 Jul 2020Department of Health and Human ServicesNational Institutes of Health$34.0MRADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVAUSAspending
15 Jan 2019Department of Veterans Affairs$1.3MIMAGING SYSTEM IGF::OT::IGFUSAspending

Company events

All 83 company events

In 12 months: 5 director or officer changes, 3 major agreements, 2 delisting notices, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
19 Nov 2026Stockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closingSame filing: shareholder vote results8-K
30 Sep 2026Signed a major agreement; A major agreement ended8-K
28 Jul 2026Signed a major agreement8-K
24 Jul 2026Delisting notice or listing transfer8-K
18 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
8 Jun 2026Director or officer change; Signed a major agreementSame filing: sold shares privately, change of control8-K
3 Jun 2026Director or officer change8-K
28 May 2026Director or officer change8-K

Reported lobbying spend: $60K in Q3 2021, $80K in Q2 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Oct 2021EndedMercury Public Affairs, LLCfor FluidigmNot statedFiling
1 Jun 2020NewMercury Public Affairs, LLCfor FluidigmIssues related to healthcareHealth issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 May 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Standard BioTools (LAB): had 10.2M shares sold short in the 28 Mar 2024 report, 3.8× the same report last year; it also reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year; and it saw 67 13F filers open a new position in the quarter ended 31 Mar 2024, 5.6× the same quarter last year. Three unrelated kinds of activity within 63 days.

  • Short interest and volume: Short interest spike, became public on 10 Apr 2024
  • Short interest and volume: Short interest spike, became public on 25 Apr 2024
  • Financials: Quarterly revenue change, became public on 14 May 2024
  • Short interest and volume: Short interest spike, became public on 10 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
  • Short interest and volume: Short interest spike, became public on 25 May 2024
  • Short interest and volume: Short interest spike, became public on 12 Jun 2024
2023-03-31: 2.7M2023-04-14: 3.2M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M
The 28 Mar 2024 report against the 24 reports before it. this reportearliernormal: 3.3M
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 10 Apr 2024

Standard BioTools had 10.2M shares sold short in the 28 Mar 2024 report, 3.8× the same report last year.

This period
10.2M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.6
Same report last year
2.7M
History used
714 days
2023-03-31: 2.7M2023-04-14: 3.2M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M
the 28 Mar 2024 report24 earlier reportsnormal: 3.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2024

Standard BioTools had 11.3M shares sold short in the 15 Apr 2024 report, 3.6× the same report last year.

This period
11.3M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
808K
How far from its usual level
+6.5
Same report last year
3.2M
History used
732 days
2023-04-14: 3.2M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M2024-04-15: 11.3M
the 15 Apr 2024 report24 earlier reportsnormal: 3.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 14 May 2024

Standard BioTools reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year.

This period
$45.5M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$26.1M
Typical spread (median absolute deviation)
$951K
How far from its usual level
+7.5
Same quarter last year
$25.1M
History used
5,023 days
2022-03-31: $26.5M2022-06-30: $18.8M2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M
the quarter ended 31 Mar 20248 earlier quartersnormal: $26.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 May 2024

Standard BioTools had 11.4M shares sold short in the 30 Apr 2024 report, 3.5× the same report last year.

This period
11.4M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
944K
How far from its usual level
+5.6
Same report last year
3.3M
History used
747 days
2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M2024-04-15: 11.3M2024-04-30: 11.4M
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

Standard BioTools saw 67 13F filers open a new position in the quarter ended 31 Mar 2024, 5.6× the same quarter last year.

This period
67 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
13
Typical spread (median absolute deviation)
4
How far from its usual level
+9.1
Same quarter last year
12
History used
3,835 days
2022-03-31: 82022-06-30: 242022-09-30: 42022-12-31: 102023-03-31: 122023-06-30: 152023-09-30: 142023-12-31: 222024-03-31: 67
the quarter ended 31 Mar 20248 earlier quartersnormal: 13

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 25 May 2024

Standard BioTools had 12.1M shares sold short in the 15 May 2024 report, 3.8× the same report last year.

This period
12.1M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.4
Same report last year
3.2M
History used
762 days
2023-05-15: 3.2M2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M2024-04-15: 11.3M2024-04-30: 11.4M2024-05-15: 12.1M
the 15 May 2024 report24 earlier reportsnormal: 3.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Jun 2024

Standard BioTools had 13.3M shares sold short in the 31 May 2024 report, 4.8× the same report last year.

This period
13.3M (the 31 May 2024 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+4.0
Same report last year
2.8M
History used
778 days
2023-05-31: 2.8M2023-06-15: 2.8M2023-06-30: 2.7M2023-07-14: 2.6M2023-07-31: 2.5M2023-08-15: 2.6M2023-08-31: 2.6M2023-09-15: 2.7M2023-09-29: 3.5M2023-10-13: 4.2M2023-10-31: 3.4M2023-11-15: 3.6M2023-11-30: 4.1M2023-12-15: 5.2M2023-12-29: 5.8M2024-01-12: 7.7M2024-01-31: 7.3M2024-02-15: 8.1M2024-02-29: 7.9M2024-03-15: 9.3M2024-03-28: 10.2M2024-04-15: 11.3M2024-04-30: 11.4M2024-05-15: 12.1M2024-05-31: 13.3M
the 31 May 2024 report24 earlier reportsnormal: 4.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

19 Feb 2019confirmed

Confirmed across sources Government contracts and Institutional holdings

Standard BioTools (LAB): won its first federal award in our data, a $1.3M Department of Veterans Affairs contract, while it saw 29 13F filers open a new position in the quarter ended 31 Dec 2018, 3.2× the same quarter last year. Two unrelated kinds of activity within 29 days.

  • Government contracts: First federal award, became public on 21 Jan 2019
  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2019
2016-12-31: 92017-03-31: 122017-06-30: 82017-09-30: 52017-12-31: 92018-03-31: 112018-06-30: 122018-09-30: 52018-12-31: 29
The quarter ended 31 Dec 2018 against the 8 quarters before it. this quarterearliernormal: 9
See the evidence (2 changes)

Government contracts: First federal award became public on 21 Jan 2019

Standard BioTools won its first federal award in our data, a $1.3M Department of Veterans Affairs contract.

Source coverage starts
7 Oct 2007
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Institutional holdings: Many funds opening a new position became public on 14 Feb 2019

Standard BioTools saw 29 13F filers open a new position in the quarter ended 31 Dec 2018, 3.2× the same quarter last year.

This period
29 (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.4
Same quarter last year
9
History used
1,918 days
2016-12-31: 92017-03-31: 122017-06-30: 82017-09-30: 52017-12-31: 92018-03-31: 112018-06-30: 122018-09-30: 52018-12-31: 29
the quarter ended 31 Dec 20188 earlier quartersnormal: 9

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Filings change

    filed a director or officer change: Stockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closing.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 19 Nov 2026Filings record

    Stockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closing

  3. 5 Nov 2026Insiders record

    Carey Thomas D. (director) bought 75,000 shares of LAB ($46,898)

  4. 30 Sep 2026Filings record

    A major agreement ended

  5. 24 Jul 2026Filings record

    Delisting notice or listing transfer

  6. 18 Jun 2026Filings record

    Director or officer change

  7. 8 Jun 2026Filings record

    Director or officer change

  8. 3 Jun 2026Filings record

    Director or officer change

  9. 28 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 28 May 2026Filings record

    Director or officer change

  11. 24 Apr 2026Filings record

    Delisting notice or listing transfer

  12. 30 Jan 2026Filings record

    Completed an acquisition or asset sale

  13. 5 Dec 2025Insiders record

    CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (director) and 7 other(s) bought 350,000 shares of LAB ($503,000) (dated 4 Dec 2025)

  14. 27 Nov 2025Insiders record

    Casdin Partners GP, LLC (director) and 7 other(s) bought 7,700,000 shares of LAB ($10.0M) (dated 26 Nov 2025)

  15. 21 Nov 2025Insiders record

    Casdin Eli (director) and 7 other(s) bought 1,075,000 shares of LAB ($1.4M) (dated 20 Nov 2025)

  16. 18 Nov 2025Insiders record

    Casdin Partners Master Fund, L.P. (director) and 7 other(s) bought 925,000 shares of LAB ($1.1M) (dated 17 Nov 2025)

  17. 13 Nov 2025Insiders record

    Casdin Partners GP, LLC (director) and 7 other(s) bought 1,175,000 shares of LAB ($1.4M) (dated 12 Nov 2025)

  18. 17 Sep 2025Filings record

    Restructuring costs announced

  19. 12 Sep 2025Insiders record

    Casdin Partners Master Fund, L.P. (director) and 7 other(s) bought 100,000 shares of LAB ($129,000) (dated 11 Sep 2025)

  20. 6 Sep 2025Insiders record

    Casdin Eli (director) and 7 other(s) bought 500,000 shares of LAB ($637,500) (dated 5 Sep 2025)

  21. 3 Sep 2025Filings record

    Restructuring costs announced

  22. 27 Aug 2025Insiders record

    Casdin Partners Master Fund, L.P. (director) and 7 other(s) bought 525,000 shares of LAB ($657,500) (dated 26 Aug 2025)

  23. 16 Aug 2025Insiders record

    Casdin Eli (director) and 7 other(s) bought 358,220 shares of LAB ($442,446) (dated 15 Aug 2025)

  24. 12 Aug 2025Filings record

    Report will be filed late (dated 11 Aug 2025)

  25. 1 Aug 2025Filings record

    Director or officer change

  26. 20 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 20 Jun 2025Filings record

    Director or officer change

  28. 8 May 2025Financials change

    spent $5.1M on capital projects in the quarter ended 31 Mar 2025, 6.5× the same quarter last year.

    Same quarter last year: $781K; its normal quarter is $958K.

    See the evidence
    This period
    $5.1M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $958K
    Typical spread (median absolute deviation)
    $528K
    How far from its usual level
    +4.1
    Same quarter last year
    $781K
    History used
    3,287 days
    2023-03-31: $1.0M2023-06-30: $838K2023-09-30: $905K2023-12-31: $78K2024-03-31: $781K2024-06-30: $1.9M2024-09-30: $2.3M2024-12-31: $3.4M2025-03-31: $5.1M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $958K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  29. 18 Mar 2025Financials change

    reported revenue of $46.7M for the quarter ended 31 Dec 2024, 1.7× the same quarter last year.

    Same quarter last year: $28.2M; its normal quarter is $27.9M.

    See the evidence
    This period
    $46.7M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $27.9M
    Typical spread (median absolute deviation)
    $2.7M
    How far from its usual level
    +4.7
    Same quarter last year
    $28.2M
    History used
    5,298 days
    2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M2024-09-30: $45.0M2024-12-31: $46.7M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $27.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  30. 5 Mar 2025Insiders record

    Casdin Capital, LLC (director) and 8 other(s) bought 4,820,959 shares of LAB ($5.2M) (dated 4 Mar 2025)

  31. 10 Jan 2025Filings record

    Director or officer change

  32. 12 Nov 2024Financials change

    reported revenue of $45.0M for the quarter ended 30 Sep 2024, 1.8× the same quarter last year.

    Same quarter last year: $25.4M; its normal quarter is $27.3M.

    See the evidence
    This period
    $45.0M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $27.3M
    Typical spread (median absolute deviation)
    $1.8M
    How far from its usual level
    +6.4
    Same quarter last year
    $25.4M
    History used
    5,206 days
    2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M2024-09-30: $45.0M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $27.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 7 Nov 2024Filings record

    Director or officer change

  34. 30 Aug 2024Filings record

    Director or officer change

  35. 30 Aug 2024Insiders record

    Casdin Private Growth Equity Fund, L.P. (director) and 8 other(s) bought 250,000 shares of LAB ($547,500) (dated 29 Aug 2024)

  36. 27 Aug 2024Insiders record

    CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (director) and 8 other(s) bought 750,000 shares of LAB ($1.5M) (dated 26 Aug 2024)

  37. 22 Aug 2024Insiders record

    Casdin Amplify Fund, LP (director) and 8 other(s) bought 1,250,000 shares of LAB ($2.3M) (dated 21 Aug 2024)

  38. 17 Aug 2024Insiders record

    Casdin Private Growth Equity Fund II, L.P. (director) and 8 other(s) bought 1,200,000 shares of LAB ($1.9M) (dated 16 Aug 2024)

  39. 14 Aug 2024Insiders record

    Casdin Amplify Fund, LP (director) and 8 other(s) bought 1,575,408 shares of LAB ($2.6M) (dated 13 Aug 2024)

  40. 13 Aug 2024Financials change

    reported revenue of $37.2M for the quarter ended 30 Jun 2024, 1.3× the same quarter last year.

    Same quarter last year: $27.7M; its normal quarter is $26.3M.

    See the evidence
    This period
    $37.2M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $26.3M
    Typical spread (median absolute deviation)
    $1.3M
    How far from its usual level
    +4.1
    Same quarter last year
    $27.7M
    History used
    5,114 days
    2022-06-30: $18.8M2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $26.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

Showing the newest 40 of 161 entries; narrow the window or the kind of data to see older ones.

Not listed: 166 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001162194
Ticker
LAB
Domain
standardbio.com
Employer name
Standard BioTools Inc. (1 unverified)
Hq location
MA|BOSTON|02109 (1 unverified)
Lobbying client
fluidigm
Name
FLUIDIGM CORP, SB Sciences Inc., Standard BioTools Australia Pty. Ltd., Standard BioTools Canada Inc. (Ontario, Canada) and 10 more
Uei
Q7U7QSDD32W4
Wikidata
Q19647855
Wikipedia
Standard BioTools
  • DOL H-1B labor condition applications and PERM certifications48 data points12 Jun 2023 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)2 records, 20 data points1 Jun 2020 to 31 Dec 2021
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)207 records12 Jan 2016 to 19 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1253 data points27 Dec 2008 to 1 Nov 2026
  • SEC Form 4 insider transactions146 records, 532 data points3 Nov 2016 to 5 Nov 2026
  • FINRA short interest (twice monthly)330 data points14 Apr 2022 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2324 data points6 Apr 2022 to 20 Nov 2026
  • USASpending.gov federal awards2 records, 1581 data points2 Oct 2007 to 16 Sep 2026
  • Wikipedia pageviews1610 data points25 Jun 2022 to 20 Nov 2026